Form 4: Director Howard Welgus Sells Arcutis Shares

Arcutis Biotherapeutics director Howard G. Welgus sold 7,144 shares of common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Director Howard G. Welgus sold 7,144 shares of Arcutis Biotherapeutics (ARQT) common stock.
• The sale was executed at a weighted average price of $22.9871 per share.
• The transaction occurred on May 1, 2026.
• Following the sale, the director retains 32,600 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on March 11, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-established 10b5-1 plan, which is a standard mechanism for insider divestment.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on sudden non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock appreciation.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity by insiders.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and is generally viewed as a standard liquidity event rather than a signal of fundamental company distress.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice for corporate insiders to avoid potential conflicts of interest regarding material non-public information.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the director's holdings.

Next Steps

• The 10b5-1 trading plan is scheduled to conclude on May 29, 2026.

Key Dates

Keywords

ARQT, Arcutis Biotherapeutics, Insider Trading, Form 4, Biotech, Director Sale